PLASMA PCSK9 AND CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES

被引：0
|
作者：
El Khoury, Petra [1 ,2 ]
Roussel, Ronan [3 ,4 ,5 ]
Fumeron, Frederic [4 ,5 ]
Velho, Gilberto [5 ]
Jacob, Marie-Paule [1 ,4 ]
Steg, Gabriel [1 ,4 ,6 ,7 ]
Potier, L. [3 ,4 ,5 ]
Ghaleb, Youmna [1 ,2 ,4 ]
Elbitar, Sandy [1 ,2 ,4 ]
Abifadel, Marianne [1 ,2 ]
Boileau, Catherine [1 ,4 ,8 ]
Marre, Michel [3 ,4 ,5 ]
Varret, Mathilde [1 ,4 ]
Hansel, Boris [3 ,4 ,5 ]
机构：
[1] INSERM, U1148, Paris, France
[2] St Joseph Univ, Beruth, Lebanon
[3] CHU Bichat, Aphp, Dept Nutr, Paris, France
[4] Denis Diderot Univ Paris 7, Paris, France
[5] INSERM, U1138, Paris, France
[6] CHU Bichat, Aphp, Dept Cardiol, Paris, France
[7] Imperial Coll, NHLI, Royal Brompton Hosp, London, England
[8] CHU Bichat, Aphp, Dept Genet, Paris, France
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.263
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAG142
引用
收藏
页码：E81 / E81
页数：1
相关论文
共 50 条
  • [41] Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study
    Massimiliano Ruscica
    Chiara Macchi
    Angelica Giuliani
    Alessandra Stefania Rizzuto
    Deborah Ramini
    Matilde Sbriscia
    Stefano Carugo
    Anna Rita Bonfigli
    Alberto Corsini
    Fabiola Olivieri
    Jacopo Sabbatinelli
    Cardiovascular Diabetology, 22
  • [42] PCSK9 inhibition in type 2 diabetes: so far so good, but not there yet
    Santos, Raul D.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05): : 377 - 379
  • [43] Targeting PCSK9 to tackle cardiovascular disease
    Hummelgaard, Sandra
    Vilstrup, Joachim Pold
    Gustafsen, Camilla
    Glerup, Simon
    Weyer, Kathrin
    PHARMACOLOGY & THERAPEUTICS, 2023, 249
  • [44] PCSK9: A Key Modulator of Cardiovascular Health
    Seidah, Nabil G.
    Awan, Zuhier
    Chretien, Michel
    Mbikay, Majambu
    CIRCULATION RESEARCH, 2014, 114 (06) : 1022 - 1036
  • [45] PCSK9 as a therapeutic target for cardiovascular disease
    Zhang, Pei-Ying
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (03) : 810 - 814
  • [46] PCSK9 INHIBITORS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
    Knijnik, Leonardo M.
    Rivera, Manuel
    Cardoso, Rhanderson
    Fernandes, Gilson
    Fernandes, Amanda
    Orringer, Carl
    Cohen, Mauricio
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 41 - 41
  • [47] PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
    Delialis, Dimitrios
    Dimopoulou, Maria-Angeliki
    Papaioannou, Maria
    Kotsira, Georgia
    Maneta, Eleni
    Mavraganis, Georgios
    Loutos, Christos
    Georgiopoulos, Georgios
    Stamatelopoulos, Kimon
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (23) : 1802 - 1824
  • [48] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
    Do, Rose Q.
    Vogel, Robert A.
    Schwartz, Gregory G.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (03)
  • [49] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
    Rose Q. Do
    Robert A. Vogel
    Gregory G. Schwartz
    Current Cardiology Reports, 2013, 15
  • [50] PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
    Tavori, Hagai
    Giunzioni, Ilaria
    Fazio, Sergio
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2015, 22 (02) : 126 - 132
12345